Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
HOME > BUSINESS
BUSINESS
- Novartis to Begin Kymriah Treatment at 2-3 Japan Sites, Looks at Gradual Expansion
April 19, 2019
- Boehringer to Remain Major Employer in Japan with As-Needed Staffer Placement
April 19, 2019
- Chugai-Originated Eczema Drug Hits Primary Goal in Japan PIII: Maruho
April 19, 2019
- Pfizer Japan Mulls Over Alternative Manufacturing Route Following Suspension of Methotrexate Production in Germany
April 19, 2019
- SanBio Unveils Positive PII Data for SB623 in Traumatic Brain Injury
April 18, 2019
- Sanofi Pushing Drugs’ Added Values to Secure Patient Access amid Rising Awareness for Economic Efficiency
April 18, 2019
- Bayer, Hokkaido Pref. Join Forces to Tackle Life Style Diseases
April 18, 2019
- Japan Pharma Market Grew 87.1% in 30 Years of Heisei Era: IQVIA
April 18, 2019
- With Ozempic Listing in Limbo, Novo Japan Chief Says Single-Dose Device Launch Unlikely This Year
April 17, 2019
- Evenity Heavily Pitched via In-Clinic Seminars in February: Anterio
April 17, 2019
- Toa Eiyo Grants China Marketing Rights for Bisono Tape to Local Firm
April 17, 2019
- Nihon Generic to Mount Aggressive Sales Campaigns Taking Advantage of Group Synergy
April 16, 2019
- Takeda Nabs Top Japanese Analyst for Global IR Team
April 16, 2019
- Mitsubishi Tanabe ALS Drug Accepted for Review in China
April 16, 2019
- Daiichi Sankyo’s Lyrica Contender Tarlige Now Available
April 16, 2019
- Bayer Japan Ethical Drug Sales Slip 1% in 2018
April 15, 2019
- AstraZeneca Japan on Track for 4 Launches in 2019, Dependence on Crestor Fades
April 15, 2019
- Amgen Looks to Debut 3 Oncology Drugs in Next 3 Years: Global Commercial Chief
April 12, 2019
- Sanofi, Yakult Close Down Zaltrap Copromotion
April 12, 2019
- Sumitomo Dainippon to Soon Decide What to Do with ADHD Med Dasotraline after Setback
April 12, 2019
ページ
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan positions its new cost-effectiveness assessment (CEA) scheme merely as a tool to complement the current drug pricing system, but…
Tatsuya Kondo, chief executive of the Pharmaceuticals and Medical Devices Agency (PMDA), is hitting the exit at the end of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…